TCTMD: PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 15, 2021

Dapagliflozin (Farxiga; AstraZeneca) eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period, the PRESERVED-HF trial shows, adding to recent evidence supporting the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibition in this difficult-to-treat population.

After 12 weeks of treatment, improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score was 5.8 points greater in patients treated with dapagliflozin versus placebo (P = 0.001), Mikhail Kosiborod, MD (Saint Luke’s Mid America Heart Institute, Kansas City, MO), reported Sunday at the Heart Failure Society of America 2021 meeting in Denver, CO.

“The effect was large, clinically meaningful, and statistically significant,” he said, noting that the finding was consistent across key subgroups defined by diabetes status, baseline LVEF, and other variables. “PRESERVED-HF, to our knowledge, is the first trial to demonstrate that [the] SGLT2 inhibitor dapagliflozin significantly improves symptoms, physical limitations, and 6-minute walking distance in patients with HFpEF,” Kosiborod said.

The results, which are in press in Nature Medicine, complement those from large trials focused on clinical outcomes, he said, “and collectively support the use of SGLT2 inhibitors as a new treatment option in HFpEF, which is a morbid condition with few therapeutic options. This, in our opinion, should have implications for clinical practice.”

Read the rest of the TCTMD article: PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Related Content

Saint Luke's Mid America Heart Institute
PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.
Cardiovascular Business: Dapagliflozin significantly improves HFpEF symptoms
Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.
Medpage Today: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients
Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.